Cipla traded at 1,397.20 this Thursday November 5th, decreasing 4.80 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Cipla lost 4.25 percent. Over the last 12 months, its price fell by 6.95 percent. Looking ahead, we forecast Cipla to be priced at 1,346.63 by the end of this quarter and at 1,254.29 in one year, according to Trading Economics global macro models projections and analysts expectations.
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.